Date:

To Whom It May Concern:

We would like your help interceding on Don Sladek’s behalf with Biogen to access the drug BIIB092,
Gosuranemab.

Don was diagnosed with Corticobasal Syndrome (also known as CBD or CBS) after a fall in June
2014, by Dr. Yvette Borderlon at University California, Los Angeles. The life expectancy is 6-8 years
and time is of the essence.
Don was enrolled in clinical trial, NCT03658135 BIIB092 in Primary Tauopathies: CBS, nfvPPA,
sMAPT, and TES (TauBasket; Principal Investigator, Dr. Adam Boxer). He received his first infusion
in January 2019 and received one every 28 days through December 11, 2019.

There are videotaped neuro exams from August 2015, through March 2020 on Don’s website:
www.treatingcbs.com

Don has had miraculous improvement in walking and balance, swallowing, motor skills, and
cognitive abilities as a result of this medication. All of this is clinically documented.

Biogen provided the drug for the trial, but did not sponsor the trial. Dr. Boxer and UCSF were the
sponsors of the trial. Biogen was concurrently sponsoring a clinical trial for Progressive
Supranuclear Palsy (PSP) patients called the PASSPORT trial, with a total of 490 patients. It is my
understanding that the trial did not meet its endpoint goals. As a result, this Biogen-sponsored trial
was halted December 13, 2019, and because the medication was halted for this study, it was also
halted for Don’s TauBasket Trial. Finally, Biogen is currently investigating the same drug in a clinical
trial for Alzheimer’s Disease called the TANGO trial, with 654 patients.

Here is our problem:

1.Biogen’s drug, BIIB092, changed Don’s life and he is quite possibly alive today only because of it.
Without it, he will degenerate and die.
2.Biogen refuses to allow access to BIIB092 due to the failure of the PSP trial.
3.Biogen has refused to acknowledge TauBasket, the UCSF-sponsored trial. The company has not
reviewed any of the data and refuses to communicate with the Sladeks or their doctors. They just
keep getting referred back to UCSF, and UCSF no longer has access to the drug—see previous
point.
4.Biogen has clearly stated to Dr. Borderlon that it will not offer the drug under Compassionate Use
or the Right To Try Act, and no one at Biogen is willing to discuss or even entertain the fact that
Don’s was the TauBasket trial and not the PSP trial.
5.We understand that we cannot force Biogen to make a drug; however, they are currently producing
BIIB092. Biogen is manufacturing BIIB092 for the TANGO Phase 2 trial for Alzheimer’s Disease,
which has an estimated enrollment of 654 patients. The trial began in May 2018 and is expected to
last 3 years and 2 months, which would mean continued manufacturing of it at least until July 2021,
with the potential for long-term extension depending on the success of the trial. Evidence of
BIIB092’s use can be found at
https://www.biogentriallink.com/en-us/clinical-indications/alzheimers-disease/tango.html

Thank you for your help in urgently addressing this problem.

_________________________
Your name
Address
Phone number